Literature DB >> 19967657

Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.

Keisuke Matsubara1, Peter Stenvinkel, Abdul Rashid Qureshi, Juan Jesús Carrero, Jonas Axelsson, Olof Heimbürger, Peter Bárány, Anders Alvestrand, Bengt Lindholm, Mohamed E Suliman.   

Abstract

BACKGROUND: The production and expression of osteoprotegerin (OPG), a bone regulating protein, is regulated by inflammatory cytokines.
METHODS: As clinical and experimental studies have implicated OPG in atherogenesis, we investigated serum OPG in relation to inflammation, endothelial dysfunction and oxidative stress markers in 265 chronic kidney disease (CKD) stage 5 patients. Cardiovascular disease (CVD), carotid plaques (n=69) and mortality (5 years) in relation to OPG were also analyzed, and the impact of inflammation on the association of OPG with mortality was evaluated.
RESULTS: OPG correlated positively with circulating surrogate markers of inflammatory, endothelial dysfunction and oxidative stress. Patients with clinical CVD or carotid plaques had higher concentrations of OPG than their respective counterparts. Increased OPG levels per se were related to higher cardiovascular and all-cause mortality even after adjustment for age, sex, C-reactive protein, diabetes mellitus and baseline CVD. Moreover, the presence of inflammation further and independently aggravated the hazard ratios (HR) for both cardiovascular (HR=2.8; 95% confidence interval [95% CI], 1.3-6.4; p=0.01) and all-cause (HR=2.5; 95% CI, 1.4-4.5; p<0.01) mortality.
CONCLUSIONS: Elevated OPG levels are associated with surrogate markers of inflammation, endothelial dysfunction, oxidative stress and CVD in CKD patients. Moreover, inflammation and OPG levels seem to have additive effects on survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19967657

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  10 in total

Review 1.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

2.  Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients.

Authors:  A Nakashima; J J Carrero; A R Qureshi; T Hirai; N Takasugi; T Ueno; Y Taniguchi; B Lindholm; N Yorioka
Journal:  Osteoporos Int       Date:  2010-09-02       Impact factor: 4.507

3.  Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival.

Authors:  Tetsu Miyamoto; Juan Jesús Carrero; Abdul Rashid Qureshi; Björn Anderstam; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin J Am Soc Nephrol       Date:  2011-02-24       Impact factor: 8.237

4.  Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.

Authors:  Pinar Demir; Fusun Erdenen; Hale Aral; Turker Emre; Sennur Kose; Esma Altunoglu; Anil Dolgun; Berrin Bercik Inal; Aydin Turkmen
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

5.  Osteoprotegerin Is a Better Predictor for Cardiovascular and All-Cause Mortality than Vascular Calcifications in a Multicenter Cohort of Patients on Peritoneal Dialysis.

Authors:  Marcela Ávila; Ma Del Carmen Prado; Renata Romero; Ricardo Córdova; Ma Del Carmen Rigo; Miguel Trejo; Carmen Mora; Ramón Paniagua
Journal:  Biomolecules       Date:  2022-04-08

6.  Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.

Authors:  M M Nascimento; S Y Hayashi; M C Riella; B Lindholm
Journal:  Braz J Med Biol Res       Date:  2014-08-22       Impact factor: 2.590

7.  Circulating Osteoprotegerin Levels Independently Predict All-cause Mortality in Patients with Chronic Kidney Disease: a Meta-analysis.

Authors:  Qing-Xiu Huang; Jian-Bo Li; Xiao-Wen Huang; Lan-Ping Jiang; Lin Huang; Hai-Wen An; Wen-Qin Yang; Jie Pang; Yan-Lin Li; Feng-Xian Huang
Journal:  Int J Med Sci       Date:  2019-09-07       Impact factor: 3.738

8.  Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study).

Authors:  Tae Ryom Oh; Chana Myeong; Su Hyun Song; Hong Sang Choi; Sang Heon Suh; Chang Seong Kim; Eun Hui Bae; Wookyung Chung; Kyu Hun Choi; Kook Hwan Oh; Seong Kwon Ma; Soo Wan Kim
Journal:  Kidney Res Clin Pract       Date:  2021-12-29

9.  Serum Osteoprotegerin Is an Independent Marker of Left Ventricular Hypertrophy, Systolic and Diastolic Dysfunction of the Left Ventricle and the Presence of Pericardial Fluid in Chronic Kidney Disease Patients.

Authors:  Katarzyna Romejko; Aleksandra Rymarz; Katarzyna Szamotulska; Zbigniew Bartoszewicz; Stanisław Niemczyk
Journal:  Nutrients       Date:  2022-07-14       Impact factor: 6.706

10.  Changes in the inflammatory and oxidative stress markers during a single hemodialysis session in patients with chronic kidney disease.

Authors:  B Sangeetha Lakshmi; N Harini Devi; M M Suchitra; P V L N Srinivasa Rao; V Siva Kumar
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.